Drawing upon a rich heritage in alpha-pharmaceutical research that gives it unrivalled expertise and insight, Algeta has the vision to be a world class oncology company bringing novel targeted medicines to patients. Algeta is a wholly owned subsidiary of Bayer

Latest News

Thomas Ramdahl appointed Managing Director of Algeta ASA (14 March 2014). Read more



Algeta recognises that its corporate potential will only be fulfilled through collaborations.

Read more
Capital Markets Day_event

New York CMD

Algeta’s New York Capital Markets Day was webcast.

Access the replay


Our people are our most important asset. Algeta is comprised of dedicated, driven employees who are developing their skills in an ever-evolving company.

Look up our vacancies
Fourth Quarter 2013 Results

Algeta’s 4Q and 2013 FY financial results are available

Find out more

Investors relations

Algeta is now part of Bayer. Please see Investor Relations for more information.

Find out more

Our Heritage

Algeta has successfully combined cutting-edge research with commercial know-how.

Read more

Contact us

If you'd like to know more about Algeta and our research, please do get in touch – we'd love to hear from you.

Get in touch